Tau Ligand Stability via Double Bond Saturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tau-specific ligands, such as PBB3, are prone to photoisomerization, making them difficult to synthesize, radiolabel, store, and handle, and they lack specificity for tau deposits over amyloid beta deposits, limiting their practicality in diagnosing and treating neurodegenerative diseases like Alzheimer's.
Innovation Solution
Development of compounds of formula (I) that selectively bind to tau deposits without photoisomerizable double bonds, ensuring stability and specificity for tau over amyloid beta deposits, allowing for effective visualization and diagnosis of tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tau-specific ligands containing photoisomerizable double bonds are used, then binding affinity for tau deposits is achieved, but stability and ease of handling deteriorate due to photoisomerization
Solution Approach 1:
The patent removes the photoisomerizable double bond from the ligand structure while retaining the core binding pharmacophore. This extraction of the problematic functional group eliminates photoisomerization susceptibility while preserving tau deposit binding affinity through maintained key structural features for tau recognition.
Solution Approach 2:
The patent modifies the chemical structure by saturating the double bond, changing the physical-chemical parameters of the ligand. This structural parameter change (from unsaturated to saturated) eliminates photoisomerization while the patent optimizes other parameters (substituents, ring systems) to maintain or enhance binding affinity for tau deposits.
2Difficulty of detecting and measuring
If general protein aggregate ligands are used, then detection capability is achieved, but specificity for tau deposits over amyloid beta deposits deteriorates
Solution Approach 1:
The patent applies local quality by designing specific molecular features at particular positions within the ligand structure that confer tau selectivity. By optimizing local structural characteristics (specific substituents, ring systems, and spatial arrangement) rather than relying on general aggregate-binding features, the ligand achieves high specificity for tau deposits while maintaining detection capability.
3Reliability
If ligands with extensive cross beta-pleated sheet conformation binding are used, then binding affinity is achieved, but selectivity among different protein aggregates deteriorates
Solution Approach 1:
The patent employs asymmetry in the ligand structure, creating an asymmetric molecular architecture that complements the specific asymmetric features of tau aggregate surfaces. This asymmetric design allows the ligand to distinguish between different aggregate types (tau versus amyloid beta) while maintaining high binding affinity for the target tau deposits through precise geometric and chemical complementarity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide excellent binding affinity and selectivity for tau deposits, enhancing diagnostic accuracy and therapeutic potential for tauopathies like Alzheimer's disease, progressive supranuclear palsy, and corticobasal degeneration, while avoiding off-target binding to MAO enzymes.
Implementation Method 1
The compounds provide excellent binding affinity and selectivity for tau deposits
Data Source
AI summary
The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate. The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy, or for the prevention or treatment of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.